🇭🇰 港交所SINOPHARMDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 18:02:00时区推断·⟳ 抓取 18:02:49·⚡ 决策 10-20 18:05:45 +2m56s·7.1 天前
国药控股H股转发子公司国药股份2026年三季报：单季净利同比增9.70%，但前三季净利仍同比降1.07%
该公告是法定季度数据转发，直接业绩主体国药股份呈现“Q3利润恢复、累计利润仍小幅下滑”的混合信号：收入仅低个位数增长，前三季归母净利-1.07%、经营现金流为负24.07亿元，且没有取得一致预期超预期证据。信号不足以支撑明确LONG；但Q3扣非利润双位数增长也不构成强空催化，因此不做。
📄 原文SINOPHARM↗ 原文
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the con…
不做 国药集团药业股份有限公司（600511.SH）
常规三季报呈混合信号：Q3利润恢复但前三季归母净利仍同比下降1.07%，现金流为负，且没有超一致预期证据；盘后公开后不适合凭标题追多，亦不构成做空催化。
不做 国药控股股份有限公司（01099.HK）
H股公告仅转发A股子公司数据，并非国药控股母公司整体业绩或指引；因子公司利润变化对母公司整体市值弹性有限，且港股已收盘，风险收益不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
国药股份Q3单季归母净利润同比+9.70%、扣非+10.59%，但前三季度归母净利润仍同比-1.07%，收入增长疲弱且经营现金流为负。消息对A股直接主体是低幅度、方向混合的常规三季报，对H股母公司更只是子公司数据转发，风险收益不足，回避。
消息传播链
- 国药控股H股在港交所披露子公司国药股份2026年第三季度主要会计数据，公告时点为北京时间18:02，港股已收盘。
- A股三季报数据在北京时间17:08已由中文财经媒体报道，核心数字与港交所公告一致，说明消息在A股盘后已进入公开传播。
关键理由
- 国药股份Q3利润同比改善，显示单季盈利边际恢复，但前三季累计净利仍下滑，难以形成单边强催化。
- 该公告对H股国药控股仅为A股子公司数据转发，缺乏足以驱动母公司估值重估的增量弹性。
主要风险
- 若卖方此前对Q3利润恢复已有充分预期，次日高开可能成为低质量兑现点。
- 经营现金流前三季度为-24.07亿元、累计ROE同比下降0.71个百分点，可能抵消单季利润改善带来的正面解读。
反向证据
先例如何影响了这次决策
对本次决策的影响:因先例不足且事件本身为低幅度混合数据，最终选择AVOID，而不是用泛化的财报反应预设仓位。
方向:未构建可用于交易的历史同类面板；常规低增长医药商业三季报的方向高度取决于是否超一致预期，而当前缺少预期差证据。
涨幅量级:没有同市场、同相位且首发锚可信的足够先例，不能用历史涨幅设定止盈止损。
形态:未能证明此类混合三季报存在稳定高开低走或持续上涨模式。
工具执行结果 · 成功 3 · 降级 1 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`sinopharm cncm 600511 third quarter 2026 results revenue net profit | 国药股份 600511 2026年第三季度报告 前三季度净利润 | 国药集团药业 2026 三季报 q3 业绩`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 降级 stock_tools HTTP · 642 ms
{ - stock_quote 成功 stock_tools HTTP · 1,864 ms
{ - web_search 成功 doubao_search · 1,604 ms
豆包搜索结果（原始查询:国药股份 600511 2026 三季报 前三季度 净利润 同比；API SearchType:web） - kb_search 失败 stock_tools HTTP · 61 ms
kb_search 服务暂不可用；这不是一条知识库命中。
原文全文
展开原文 · 3,503 字
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no
responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.
ANNOUNCEMENT
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL
INDICATORS OF SINOPHARM (CNCM LTD)
FOR THE THIRD QUARTER OF 2026
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and
Futures Ordinance (Chapter 571, Laws of Hong Kong).
Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the
“Company”) dated 20 October 2026 (the “Announcement”) in relation to the 2026 third
quarterly report of China National Medicines Corporation Ltd. (國藥集團藥業股份有限公司)
(“SINOPHARM (CNCM LTD)”), a subsidiary of the Company and whose A shares are listed
on the Shanghai Stock Exchange (stock code: 600511).
The board of directors of the Company would like to draw the attention of its shareholders and
the public investors to the following principal unaudited accounting data and financial
indicators of SINOPHARM (CNCM LTD) for the third quarter of 2026 as set out in the
Announcement.
* The Company is registered as a non-Hong Kong company under the Hong Kong Companies
Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF
SINOPHARM (CNCM LTD)
Unit: Yuan
Currency: RMB
Reporting Period
Revenue
Changes of
the
Reporting
Period over
the same
period of last
year (%)
13,878,085,353.85
Changes of the
period from the
From the
beginning of
beginning of the
the year to the
year to the end of
end of the
the Reporting
Reporting
Period
Period over the
same period of
last year (%)
0.95 40,606,422,021.73
3.11
Net profit
attributable to
shareholders of the
listed company
596,464,172.79
9.70
1,476,233,652.87
-1.07
Net profit
attributable to
shareholders of the
listed company
after deducting
non-recurring
gains and losses
595,690,042.65
10.59
1,475,460,390.97
0.36
Net cash flow
arising from
operating activities
N/A
N/A
-2,406,818,944.22
N/A
Basic earnings per
share (Yuan/share)
0.7906
9.71
1.9566
-1.07
Diluted earnings
per share
(Yuan/share)
0.7906
9.71
1.9566
-1.07
3.12
Increased by
0.06
percentage
point
7.79
Decreased by
0.71 percentage
point
Weighted average
return on net
assets (%)
2
At the end of the
Reporting Period
At the end of last year
Changes of the end
of
the Reporting
Period
over the end of last
year (%)
Total assets
36,813,323,715.90
36,685,023,982.59
0.35
Equity
attributable to
shareholders of
the listed
company
19,408,289,559.64
18,544,719,561.48
4.66
Note: “Reporting Period” refers to the three months ended 30 September 2026.
By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman
Shanghai, the PRC
20 October 2026
As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr.
Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr.
Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the
independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr.
Shi Shenghao and Mr. Chen Weiru.
3
responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.
ANNOUNCEMENT
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL
INDICATORS OF SINOPHARM (CNCM LTD)
FOR THE THIRD QUARTER OF 2026
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and
Futures Ordinance (Chapter 571, Laws of Hong Kong).
Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the
“Company”) dated 20 October 2026 (the “Announcement”) in relation to the 2026 third
quarterly report of China National Medicines Corporation Ltd. (國藥集團藥業股份有限公司)
(“SINOPHARM (CNCM LTD)”), a subsidiary of the Company and whose A shares are listed
on the Shanghai Stock Exchange (stock code: 600511).
The board of directors of the Company would like to draw the attention of its shareholders and
the public investors to the following principal unaudited accounting data and financial
indicators of SINOPHARM (CNCM LTD) for the third quarter of 2026 as set out in the
Announcement.
* The Company is registered as a non-Hong Kong company under the Hong Kong Companies
Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF
SINOPHARM (CNCM LTD)
Unit: Yuan
Currency: RMB
Reporting Period
Revenue
Changes of
the
Reporting
Period over
the same
period of last
year (%)
13,878,085,353.85
Changes of the
period from the
From the
beginning of
beginning of the
the year to the
year to the end of
end of the
the Reporting
Reporting
Period
Period over the
same period of
last year (%)
0.95 40,606,422,021.73
3.11
Net profit
attributable to
shareholders of the
listed company
596,464,172.79
9.70
1,476,233,652.87
-1.07
Net profit
attributable to
shareholders of the
listed company
after deducting
non-recurring
gains and losses
595,690,042.65
10.59
1,475,460,390.97
0.36
Net cash flow
arising from
operating activities
N/A
N/A
-2,406,818,944.22
N/A
Basic earnings per
share (Yuan/share)
0.7906
9.71
1.9566
-1.07
Diluted earnings
per share
(Yuan/share)
0.7906
9.71
1.9566
-1.07
3.12
Increased by
0.06
percentage
point
7.79
Decreased by
0.71 percentage
point
Weighted average
return on net
assets (%)
2
At the end of the
Reporting Period
At the end of last year
Changes of the end
of
the Reporting
Period
over the end of last
year (%)
Total assets
36,813,323,715.90
36,685,023,982.59
0.35
Equity
attributable to
shareholders of
the listed
company
19,408,289,559.64
18,544,719,561.48
4.66
Note: “Reporting Period” refers to the three months ended 30 September 2026.
By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman
Shanghai, the PRC
20 October 2026
As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr.
Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr.
Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the
independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr.
Shi Shenghao and Mr. Chen Weiru.
3
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
7ce0a0d5ad· 2026-10-20 18:05 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前